• No results found

University of Groningen Chronic limb-threatening ischemia Ipema, Jetty

N/A
N/A
Protected

Academic year: 2021

Share "University of Groningen Chronic limb-threatening ischemia Ipema, Jetty"

Copied!
2
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

University of Groningen

Chronic limb-threatening ischemia Ipema, Jetty

DOI:

10.33612/diss.170945328

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date: 2021

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Ipema, J. (2021). Chronic limb-threatening ischemia: Optimizing endovascular and medical treatment. University of Groningen. https://doi.org/10.33612/diss.170945328

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

(2)

Stellingen behorende bij het proefschrift

1. So far, drug-coated balloons have no added value in the treatment of below-the-knee arterial disease compared with standard

percutaneous balloon angioplasty. This thesis

2. The strategy of ‘leaving nothing behind’ with bioresorbable scaffolds for below-the-knee arterial disease is promising. This thesis

3. There is a substantial lack of evidence regarding medical therapies for patients with CLTI, especially for no-option CLTI patients. This thesis

4. (Inter)national consensus is lacking regarding type and duration of antiplatelet therapy after infrainguinal endovascular interventions. This thesis

5. Dual antiplatelet therapy may be preferred over single antiplatelet therapy for patients who undergo below-the-knee treatment. This thesis

6. Due to Covid-19 the importance of scientific research has been emphasized.

7. Uit onderzoek is gebleken dat onderzoeken veel leuker is dan antwoorden vinden. Loesje

Referenties

GERELATEERDE DOCUMENTEN

36 Secondary prevention has been shown to significantly reduce major adverse cardiac events, major adverse limb events, and mortality, but most patients with PAD do

The following keywords were used: below the knee, infrapopliteal, tibial arteries, tibial artery, crural, peripheral arterial disease, peripheral artery disease, critical

This patency rate was better compared with hybrid drug coverage with the Eluvia stent and DCB or the combination of Eluvia and BMS or POBA, while the total lesion coverage group

In the AMS INSIGHT study (Bioabsorbable Metal Stent Investigation in Chronic Limb Ischemia Treatment), 117 CLTI patients (Rutherford category 4 or 5) with 149 lesions

The keywords used were bioabsorbable stent, bioabsorbable scaffold, bioresorbable scaffold, bioresorbable stent, biodegradable stent, biodegradable scaffold, peripheral

This pooled analysis showed that the Absorb BVS can be safely used for the treatment of patients with CLTI due to infrapopliteal artery disease with favorable rates of

This study investigated the reliability of 2DPA as a foot perfusion measurement tool in patients with CLTI and demonstrated excellent repeatability and intra- and

A meta-analysis of ten studies comparing bone marrow stem cell therapy with placebo in patients with CLTI showed no significant differences in major amputation, mortality and